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OBJECTIVE: The purposes of this study were to determine the coexistence of mastalgia and fibromyalgia, to
investigate the effects of this combination on pain patterns, and to discuss the status of breast pain in the
diagnostic algorithm of fibromyalgia syndrome.
METHODS: Sixty-one female patients reporting breast pain during the last three months and 53 female patients
diagnosed with fibromyalgia syndrome were enrolled in this study. The Breast Pain Questionnaire was
administered to all participants in the mastalgia group and to those in the fibromyalgia syndrome group who
had experienced mastalgia during the past three months. The patients in the fibromyalgia syndrome group
were evaluated using the 2010 preliminary American College of Rheumatology classification criteria. All of the
patients in the mastalgia group were evaluated for the diagnosis of fibromyalgia syndrome by a single
physiatrist. The coexistence and pain patterns of mastalgia and fibromyalgia were assessed statistically.
RESULTS: Approximately half of the patients with fibromyalgia syndrome (47.2%) reported having mastalgia at
the time of admission and 37.7% of the patients with mastalgia met the diagnostic criteria for fibromyalgia
syndrome. The patients with mastalgia in the fibromyalgia syndrome group had significantly higher total breast
pain scores compared with the women in the mastalgia group. In addition, the patients with fibromyalgia
syndrome in the mastalgia group had significantly higher Widespread Pain Index and Symptom Severity Scale
scores than the patients with fibromyalgia syndrome.
CONCLUSI˙ONS: We suggest that mastalgia can be an aspect of the central sensitivity syndrome and can be
added to the somatic symptoms of fibromyalgia.
KEYWORDS: Breast Pain; Fibromyalgia; Mastalgia; Breast Pain Questionnaire; Fibromyalgia Classification
Criteria.
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’ INTRODUCTION
Mastalgia, also referred to as mastodynia or breast pain, is
a common compliant with a reported prevalence of 66% to
80% among women (1,2). Mastalgia is usually associated
with benign breast conditions, such as fibrocystic breast
disease, premenstrual syndrome and psychological disorders;
less commonly, it is a sign of malignancy (3,4). Mastalgia is
usually classified into two different types: cyclic and non-
cyclic (5). Cyclic breast pain is the more common type; it is
associated with menstrual periods and responds well to
hormonal therapies (6). The non-cyclical type affects a small
proportion of women without premenstrual exacerbations; its
underlying physiopathology appears to be less clear than that
of cyclic mastalgia. As a result, the etiopathogenesis of this
commonly observed clinical entity is still unclear, but nutritional,
hormonal and psychological causes are thought to play a role (7).
Most previous studies of mastalgia have focused primarily
on its treatment modalities; however, a limited number of
studies have investigated its psychological basis and its
association with various psychological conditions or chronic
pain syndromes (1,8). One of these is fibromyalgia syndrome
(FMS), which is well known as a chronic musculoskeletal
pain condition. Therefore, we aimed to explore the relation-
ship between mastalgia and FMS, both of which are
commonly found among female populations worldwide.
’ MATERIALS AND METHODS
Study design
Between July 2014 and December 2014, 114 consecutive
women aged 18 years and older were included in this study,
which took place in a tertiary-care university hospital. Sixty-
one female patients presenting to our surgery departmentDOI: 10.6061/clinics/2015(11)03
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with breast pain of at least 3 months duration and 53
consecutive female patients admitted to the Physical Medicine
and Rehabilitation Department with complaints of FMS were
classified as the mastalgia group and the FMS group,
respectively. The exclusion criteria were the presence of a
previous organic breast disease, such as cancer, abscess, or a
known breast pathology; previous breast surgery; pregnancy;
lactation and an inability to complete the questionnaires.
The patients’ age, educational status, marital status, duration
of breastfeeding, menopausal status, hormone replacement
therapy (HRT) use, employment status and comorbid diseases
were recorded in detail.
All patients with complaints of breast pain were evaluated
by the same surgeon and imaging methods such as
mammography and/or ultrasonography were used when
needed. To assess mastalgia, the Breast Pain Questionnaire
(BPQ), a reliable and detailed tool, was administered to all of
the participants in the mastalgia group and to those in the
FMS group who reported having suffered from mastalgia in
the 3 months prior to admission. This questionnaire provides
information about the characteristics of breast pain, such as
the pain’s pattern, degree and relationship with menstruation.
Furthermore, it is accepted as a quick assessment tool that
physicians can use in daily practice (9). A final breast pain
score (%totalBP) composed of four distinct scores (%Qtotal,
%PPI, %VAS and %QOL, described below) was calculated for
each patient with mastalgia. %Qtotal is the sum of the sensory
and affective scores obtained from each sensory and affective
descriptor. %PPI is the present pain index, %VAS is a score
obtained using a visual analog scale and %QOL is a score
based on quality of life questions. As a result, breast pain was
classified into 3 severity groups based on the BPQ score: mild
(0-100), moderate (101-200) and severe (4200).
The diagnosis of FMS was based on the 2010 preliminary
American College of Rheumatology classification criteria
(10). The criteria provide a current and detailed diagnostic
tool consisting of two main parts: a widespread pain index
(WPI) and a symptom severity scale score (SSS score). The
WPI is a score between 0 and 19 related to specific painful
areas on the body. The SSS score is based on the severity of
fatigue, unrefreshing sleep and cognitive status, plus the
presence of various somatic symptoms such as muscle
weakness, nausea, vomiting, depression, insomnia, loss of
appetite and thinking or memory problems.
An informed consent form was obtained from all partici-
pants. The study protocol was approved by the Medical
Ethics Committee of Turgut Ozal University, Faculty of
Medicine, Ankara, Turkey (permit number, date: 99950669/
232, 30.06.2014).
Statistical analysis
The Statistical Package for the Social Sciences (SPSS 21.0
software, Chicago, IL, USA) standard version was used for
the data analyses. Descriptive analysis was performed for
socio-demographic data and pain characteristics, and the
statistical results were presented as the mean ± SD/
percentages for continuous variables and number/percen-
tage for categorical variables. The Mann Whitney U test and
chi-square test were used to investigate the differences
between the main groups and subgroups. The significance
level was accepted as po0.05.
’ RESULTS
Sixty-one female patients with mastalgia aged 18 to
60 years and fifty-three female patients with FMS aged 18 to
48 years were included in this study. All of the patient
characteristics are presented in Table 1. The mean ages of
the mastalgia and FMS groups were similar (35.02 and 34.38
years, respectively) and the majority of the women in both
groups were premenopausal (73.8% and 77.4%, respectively).
Three patients in the mastalgia group and two patients in the
FMS group received HRT for postmenopausal symptoms
and there was no significant difference between the groups
in this aspect (p=0.567). In addition, no significant differences
were found between the two groups with respect to other
patient characteristics, including educational status, marital
status, employment status, duration of breastfeeding and
presence of comorbid disease.
Regarding the main outcomes of this study, 23 women
(37.7%) were diagnosed with FMS in the mastalgia group
according to the current diagnostic criteria and mastalgia was
found in 25 patients (47.2%) in the FMS group (Figure 1).
Table 1 - Comparison of the patient characteristics of the two groups.
Mastalgia group (n=61) Fibromyalgia syndrome group (n=53) p
Age (years) 35.02 ± 9.90 34.38 ± 8.20 0.930
Educational status 0.425
Primary/secondary school 17 (27.9%) 20 (37.7%)
High school 26 (42.6%) 22 (41.5%)
University 18 (29.5%) 11 (20.8%)
Marital status 0.535
Single 12 (19.7%) 11 (20.8%)
Married 49 (80.3%) 42 (79.2%)
Employment status 0.507
Housewife 37 (60.7%) 33 (62.2%)
Employed 24 (39.3%) 20 (37.8%)
Menopausal status 0.777
Premenopausal 45 (73.8%) 41 (77.4%)
Perimenopausal 9 (14.8%) 8 (15.1%)
Postmenopausal 7 (11.5%) 4 (7.5%)
Duration of breastfeeding (mo.) 19.87 ± 20.40 24.17 ± 21.04 0.289
Comorbid disease 4 (6.5%) 3 (5.6%) 0.587
HRT 3 (4.9%) 2 (3.7%) 0.567
Data are presented as the mean± SD for age and duration of breastfeeding; n (%) for other variables. mo.: months, HRT: hormone replacement therapy.
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All of the participants in the mastalgia group and the
patients in the FMS group who suffered from mastalgia were
compared in terms of the type of mastalgia, the severity of
breast pain, and BPQ scores, including %Qtotal, %PPI,
%VAS, %QOL, and %totalBP (Table 2). These two groups
were similar with respect to age (p=0.790), educational status
(p=0.743), marital status (p=0.771), employment status
(p=0.626), menopausal status (p=0.822), duration of breast-
feeding (p=0.392), presence of comorbid disease (p=1.000)
and HRT (p=0.553). Cyclic mastalgia was the most frequent
form in both groups. No significant difference was found
between the women in the mastalgia group and those with
mastalgia in the FMS group with respect to the type of
mastalgia (p=0.321). Among the BPQ scores, the %Qtotal
(p=0.029) and %VAS (p=0.010) were significantly higher
among the subjects with mastalgia in the FMS group;
however, there was no difference between the two groups
in terms of %PPI (p=0.129) and %QOL (p=0.089). It was clear
that the subjects with mastalgia in the FMS group had
significantly higher totalBP scores compared with the
patients in the mastalgia group (p=0.012). In addition, the
severity of mastalgia, determined using the totalBP score,
was similar for these two subgroups, with a p-value of 0.06.
All of the subjects in the FMS group and the participants
who met the criteria for FMS in the mastalgia group were
compared with respect to the WPI and SSS scores (Table 3).
These two subgroups were similar in terms of age (p=0.412),
educational status (p=0.591), marital status (p=0.172),
employment status (p=0.179), menopausal status (p=0.752),
duration of breastfeeding (p=0.986), presence of comorbid
disease (p=0.648) and HRT (p=0.667). The mean WPI values
for these subgroups were 8.43 and 9.87, respectively. The
patients diagnosed with FMS in the mastalgia group had
significantly higher a WPI compared with the women in the
FMS group (p=0.024). In addition, the SSS scores of these two
subgroups differed significantly (p=0.000). However, the
scores for three SSS score subscales (fatigue [p=0.188],
waking unrefreshed [p=0.314], and cognitive symptoms
[p=0.159]) were statistically similar for the FMS group and
the patients in the mastalgia group who met the criteria for
FMS. In contrast, the somatic symptom score was signifi-
cantly higher for the patients with FMS in the mastalgia
group than for the patients in the FMS group (p=0.000).
’ DISCUSSION
While mastalgia is a sign of an organic breast disease, it
also has a possible psychological background that is not fully
understood. In addition, mastalgia is known to be strongly
associated with high stress levels (11). Unexplained pain
syndromes, such as FMS and functional gastrointestinal
disorders, including irritable bowel disease and dyspepsia,
are also known to be stress-based diseases. Among these,
irritable bowel syndrome has been found to be related to
FMS, and both have a female predominance (12). Another
study reported a strong link between patients with FMS and
gastrointestinal disorders (13). Therefore, similar unknown
mechanisms may play significant roles in the physiopatho-
genesis of mastalgia and similar stress-based diseases.
Among those clinical entities, FMS has not been sufficiently
investigated in terms of its association with mastalgia.
However, the sociodemographic and clinical similarities
between mastalgia and FMS suggest a possible relationship
between them.
Figure 1 - The number of patients diagnosed with fibromyalgia syndrome in the mastalgia group (A) and the number of patients with
mastalgia in the FMS group (B).
Table 2 - Comparison of the breast pain patterns of the patients with mastalgia in the two groups.
Mastalgia group (n=61) Patients with mastalgia in the fibromyalgia syndrome group (n=25) p
Age (years) 35.02 ± 9.902 33.76 ± 8.227 0.790
Type of breast pain 0.321
Cyclic 42 (68.9%) 14 (56.0%)
Non-cyclic 19 (31.1%) 11 (44.0%)
BPQ scores
%Qtotal 30.07 ± 15.788 42.32 ± 23.167 0.029
%PPI 16.75 ± 7.824 19.52 ± 7.784 0.129
%VAS 51.80 ± 18.029 62.00 ± 13.540 0.010
%QOL 33.21 ± 20.239 40.40 ± 19.333 0.089
%totalBP 131.90 ± 56.334 164.16 ± 53.330 0.012
Severity of mastalgia 0.060
Mild 23 (37.7%) 3 (12.0%)
Moderate 27 (44.3%) 15 (60.0%)
Severe 11 (18.0%) 7 (28.0%)
Data are presented as the mean ± SD for age and BPQ scores; n (%) for other variables.
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FMS, which is a common health problem, is defined as
ongoing widespread pain of at least three months’ duration
combined with fatigue, sleep problems and various somatic
symptoms. Although FMS is widely known as a rheumatic
disease, it is also accepted as one of the central sensitivity
syndromes (14). It mainly affects women and the associated
chronic pain limits their quality of life. Therefore, FMS is a
clinical condition that leads to significant socioeconomic
problems worldwide. Additionally, patients with FMS often
have various associated psychiatric disorders because of the
physiological characteristics of the syndrome (15,16). In a
study by Fietta et al., FMS was shown to be related to anxiety
disorder and depression; up to 80% of FMS patients had
anxiety or depression (17). Arnold also noted that psychiatric
comorbidities negatively affect the severity and course of
FMS (18). In our study, only two patients in the FMS group
were taking psychiatric drugs at the time of admission;
however, approximately one-quarter of the patients with
FMS had a history of a psychiatric disorder at some point in
their lives. Similarly, anxiety disorder and depression were
found in a high percentage of the mastalgia patients in a
study by Colegrave (8). To our knowledge, the first
comprehensive clinical study on the association of mastalgia
with psychiatric conditions was reported by Preece et al. in
1978. He found that treatment-resistant patients with breast
pain had higher scores for anxiety and depression (19). Later,
a 1993 study by Jenkins et al. showed that 21 out of 25
patients with treatment-resistant breast pain met the criteria
for any psychiatric diagnosis. The authors recommended
psychiatric evaluation and antidepressant therapy for this
group of mastalgia patients based on their findings (20).
Similarly, 13 out of 61 mastalgia patients in our study had
been previously treated for a psychiatric disorder. To the best
of our knowledge, only two clinical studies on the relation-
ship between mastalgia and FMS have been reported to date
(1,21). One is the 2006 study by Johnson et al, which
demonstrated the association between mastalgia and various
chronic pain disorders, including irritable bowel syndrome,
chronic pelvic pain and FMS (1). However, the severity of
mastalgia was not evaluated using a current scoring system;
instead, mastalgia was only classified as frequent or
infrequent. Additionally, the authors did not determine the
prevalence of mastalgia in patients with FMS. Despite these
limitations, one of the main outcomes of their study was the
finding of a possible association between a common form of
mastalgia and unexplained pain syndromes. The second
study to demonstrate a link between mastalgia and FMS was
reported by Genc et al. in 2011 (21). In that study, the BPQ
was used as a relatively objective assessment tool for
evaluating mastalgia. We also used this questionnaire to
evaluate breast pain; however, our study was differentiated
by its use of new diagnostic criteria for FMS. In contrast, the
authors of the previous study used the 1990 American
College of Rheumatology classification criteria, the Fibro-
myalgia Impact Questionnaire and Short Form-36 to
diagnose and assess FMS. The 1990 criteria were based on
a count of tender points at different body sites. In 2010, these
criteria were abandoned in favor of a new diagnostic
classification system that placed increased emphasis on the
patient symptoms published by The American College of
Rheumatology (10). This current diagnostic tool includes
both the WPS and SSS scores, which allows physicians to
assess various polysymptomatic conditions, including fati-
gue, sleep status, cognitive status and various somatic
symptoms. Therefore, the 2010 preliminary criteria provide
more information about symptom variability in patients with
FMS and are more sensitive than the 1990 criteria (22). In the
study by Genc et al., two distinct clinical entities, mastalgia
and FMS, were found to frequently coexist. According to that
study’s findings, 36% of the mastalgia patients met the
criteria for FMS, while 42% of the patients with FMS suffered
from mastalgia. We found a higher association between
mastalgia and FMS than the previous authors did. From
our point of view, the higher rates of FMS observed in our
study were a consequence of the new FMS classification
system. Approximately half of the patients with FMS in
our study had mastalgia; this ratio may be comparable to
that of the general population because the majority of
women suffer from breast pain at some point in their lives
(23). It is important to note that patients undergoing HRT
were not removed from our study. In fact, HRT is a known
cause of mastalgia, but it was not used as an exclusion
criterion because the number of patients undergoing HRT
was very low in both groups and had no effect on the
statistical results.
The total breast pain scores of the patients with mastalgia
in the FMS group were significantly higher than those of the
women in the mastalgia group. The scores for the other scale,
severity of breast pain, did not reach statistical significance,
but their p-value of 0.060 was very close to the significance
level. However, Genc et al. found that these scores were
similar for the two groups (21). These two conflicting results
may be the result of the limited number of patients enrolled
in the study; however, the coexistence of these two disorders
seems to aggravate the severity of mastalgia. Furthermore,
these results are of great importance to the mastalgia
treatment approach. It is well known that many hormonal
and non-hormonal agents have been used in mastalgia
treatment (4); however, none of them offers a total cure. In
addition, widespread pain assessment is usually neglected in
mastalgia patients and may contribute to the failure of
mastalgia treatment. Therefore, patients with mastalgia
Table 3 - Comparison of the patients with fibromyalgia syndrome in the two groups.
Fibromyalgia syndrome
group (n=53)
Patients with fibromyalgia syndrome in
the mastalgia group (n=23)
p
Age (years) 34.38 ± 8.200 36.61 ± 9.389 0.412
WPI 8.43 ± 1.896 9.87 ± 2.912 0.024
SSS score 6.34 ± 1.568 8.00 ± 2.276 0.000
Fatigue score 2.06 ± 0.745 2.30 ± 0.635 0.188
Waking unrefreshed score 2.04 ± 0.678 2.17 ± 0.887 0.314
Cognitive symptoms score 1.25 ± 0.757 1.48 ± 0.730 0.159
Somatic symptoms score 1.02 ± 1.009 2.04 ± 0.878 0.000
Data are presented as the mean ± SD for all variables.
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should be evaluated for the presence of FMS to increase the
likelihood of successful pain treatment.
The other main finding of our work is the high prevalence
of FMS in mastalgia patients (37.7%) compared with the
general population. This result may reveal a common
etiopathogenic link between mastalgia and FMS. In addition,
when the FMS classification scores of the groups were
analyzed, the WPI and SSS scores differed significantly
between the FMS group and the patients with FMS in the
mastalgia group. Additionally, a statistically significant
difference was found between these groups regarding their
somatic symptom scores. The statistically higher scores of the
patients with FMS in the mastalgia group may indicate that
mastalgia could be included among the somatic symptoms in
the diagnostic algorithm for FMS. Additionally, these
findings can help to extend the current FMS concept and
the consideration of mastalgia could change our approach to
FMS treatment. Further large-scale clinical studies could help
to clarify the association between mastalgia and the success
of pain management in FMS.
This study showed that the coexistence of mastalgia and
FMS is more frequent than previously estimated, suggesting
that these two disorders could share some unknown
common mechanisms in their etiopathogenesis. Additionally,
mastalgia could be a part of central sensitivity syndrome and
could be included among the somatic symptoms in the
fibromyalgia criteria based on its high prevalence in patients
with FMS. Therefore, patients with FMS should also be asked
about the presence of mastalgia during routine examinations.
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